Patents Assigned to Wuhan Sanli BioTechnology Company Limited
  • Respiratory syncytial virus vaccine
    Patent number: 10232033
    Abstract: A respiratory syncytial virus (RSV) vaccine comprising a recombinant fusion protein antigen. In one embodiment, the recombinant fusion protein antigen comprises a phosphoprotein (P) moiety, wherein the P moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 2 or SEQ ID NO 4; and a flagellin moiety, wherein the flagellin moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 8; whereby the P moiety and flagellin moiety are covalently coupled so as to form a linear polypeptide.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 19, 2019
    Assignee: Wuhan Sanli BioTechnology Company Limited
    Inventors: Huimin Yan, Jingyi Yang, Bali Zhao
  • RESPIRATORY SYNCYTIAL VIRUS VACCINE
    Publication number: 20190000962
    Abstract: A respiratory syncytial virus (RSV) vaccine comprising a recombinant fusion protein antigen. In one embodiment, the recombinant fusion protein antigen comprises a phosphoprotein (P) moiety, wherein the P moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 2 or SEQ ID NO 4; and a flagellin moiety, wherein the flagellin moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 8; whereby the P moiety and flagellin moiety are covalently coupled so as to form a linear polypeptide.
    Type: Application
    Filed: October 31, 2016
    Publication date: January 3, 2019
    Applicant: Wuhan Sanli BioTechnology Company Limited
    Inventors: Huimin YAN, Jingyi YANG, Bali ZHAO